{"pmid":32312163,"title":"Impact of the COVID-19 Pandemic on the Management of Head and Neck Malignancies.","text":["Impact of the COVID-19 Pandemic on the Management of Head and Neck Malignancies.","The impact of the coronavirus disease 2019 (COVID-19) pandemic on the management of head and neck cancer must be addressed. Immediate measures to reduce transmission rates and protect patients and providers take priority and necessitate some delays in care, particularly for patients with mild symptoms or less aggressive cancers. However, strict guidelines have yet to be developed, and many unintentional delays in care are to be expected based on the magnitude of the looming public health crisis. The medical complexity of head and neck cancer management may lead to prolonged delays that worsen treatment outcomes. Therefore, those caring for patients with head and neck cancer must take action to reduce these negative impacts as the country rallies to overcome the challenges posed by this pandemic.","Otolaryngol Head Neck Surg","Werner, Michael T","Carey, Ryan M","Albergotti, W Greer","Lukens, John N","Brody, Robert M","32312163"],"abstract":["The impact of the coronavirus disease 2019 (COVID-19) pandemic on the management of head and neck cancer must be addressed. Immediate measures to reduce transmission rates and protect patients and providers take priority and necessitate some delays in care, particularly for patients with mild symptoms or less aggressive cancers. However, strict guidelines have yet to be developed, and many unintentional delays in care are to be expected based on the magnitude of the looming public health crisis. The medical complexity of head and neck cancer management may lead to prolonged delays that worsen treatment outcomes. Therefore, those caring for patients with head and neck cancer must take action to reduce these negative impacts as the country rallies to overcome the challenges posed by this pandemic."],"journal":"Otolaryngol Head Neck Surg","authors":["Werner, Michael T","Carey, Ryan M","Albergotti, W Greer","Lukens, John N","Brody, Robert M"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312163","week":"202017|Apr 20 - Apr 26","doi":"10.1177/0194599820921413","keywords":["covid-19","sars-cov-2","head and neck cancer"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664714520185012224,"score":8.518259,"similar":[{"pmid":32298006,"title":"Care of Immunocompromised Patients with Head and Neck Cancer During the COVID-19 Pandemic: Two Challenging and Informative Clinical Cases.","text":["Care of Immunocompromised Patients with Head and Neck Cancer During the COVID-19 Pandemic: Two Challenging and Informative Clinical Cases.","BACKGROUND AND METHODS: There is an added level of complexity in the management of head and neck cancer patients with underlying immunosuppressive disorders during the COVID-19 pandemic. Head and neck oncologists are tasked with balancing the dual risks of cancer progression in the setting of impaired tumor immunity and increased susceptibility to life-threatening complications from exposure to viral infection for patients and providers. Through two cases of immunocompromised patients with newly diagnosed head and neck malignancies, we aim to provide guidance to clinicians struggling with how to best counsel and manage this unique subset of patients under these difficult circumstances. RESULTS: After careful consideration of the options, we took different approaches in the care of these two patients. CONCLUSIONS: Ultimately, there is no uniform set of rules to apply to this heterogeneous group of immune-compromised patients. We provide some general principles to help guide patient management during the current pandemic. This article is protected by copyright. All rights reserved.","Head Neck","Civantos, Alyssa M","Carey, Ryan M","Lichtenstein, Gary R","Lukens, John N","Cohen, Roger B","Rassekh, Christopher H","32298006"],"abstract":["BACKGROUND AND METHODS: There is an added level of complexity in the management of head and neck cancer patients with underlying immunosuppressive disorders during the COVID-19 pandemic. Head and neck oncologists are tasked with balancing the dual risks of cancer progression in the setting of impaired tumor immunity and increased susceptibility to life-threatening complications from exposure to viral infection for patients and providers. Through two cases of immunocompromised patients with newly diagnosed head and neck malignancies, we aim to provide guidance to clinicians struggling with how to best counsel and manage this unique subset of patients under these difficult circumstances. RESULTS: After careful consideration of the options, we took different approaches in the care of these two patients. CONCLUSIONS: Ultimately, there is no uniform set of rules to apply to this heterogeneous group of immune-compromised patients. We provide some general principles to help guide patient management during the current pandemic. This article is protected by copyright. All rights reserved."],"journal":"Head Neck","authors":["Civantos, Alyssa M","Carey, Ryan M","Lichtenstein, Gary R","Lukens, John N","Cohen, Roger B","Rassekh, Christopher H"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298006","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hed.26165","keywords":["covid-19","airway","head and neck cancer","immunosuppression","risk management"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664641388434685952,"score":478.28433},{"pmid":32298036,"title":"A Framework for Prioritizing Head and Neck Surgery during the COVID-19 Pandemic.","text":["A Framework for Prioritizing Head and Neck Surgery during the COVID-19 Pandemic.","The COVID-19 pandemic has placed an extraordinary demand on the United States healthcare system. Many institutions have cancelled elective and non-urgent procedures to conserve resources and limit exposure. While operational definitions of elective and urgent categories exist, there is a degree of surgeon judgment in designation. In the present commentary, we provide a framework for prioritizing head and neck surgery during the pandemic. Unique considerations for the head and neck patient are examined including risk to the oncology patient, outcomes following delay in head and neck cancer therapy, and risk of transmission during otolaryngologic surgery. Our case prioritization criteria consist of four categories: urgent - proceed with surgery, less urgent - consider postpone >30 days, less urgent - consider postpone 30-90 days, and case-by-case basis. Finally, we discuss our preoperative clinical pathway for transmission mitigation including defining low-risk and high-risk surgery for transmission and role of preoperative COVID-19 testing. This article is protected by copyright. All rights reserved.","Head Neck","Topf, Michael C","Shenson, Jared A","Holsinger, F Christopher","Wald, Samuel H","Cianfichi, Lisa J","Rosenthal, Eben L","Sunwoo, John B","32298036"],"abstract":["The COVID-19 pandemic has placed an extraordinary demand on the United States healthcare system. Many institutions have cancelled elective and non-urgent procedures to conserve resources and limit exposure. While operational definitions of elective and urgent categories exist, there is a degree of surgeon judgment in designation. In the present commentary, we provide a framework for prioritizing head and neck surgery during the pandemic. Unique considerations for the head and neck patient are examined including risk to the oncology patient, outcomes following delay in head and neck cancer therapy, and risk of transmission during otolaryngologic surgery. Our case prioritization criteria consist of four categories: urgent - proceed with surgery, less urgent - consider postpone >30 days, less urgent - consider postpone 30-90 days, and case-by-case basis. Finally, we discuss our preoperative clinical pathway for transmission mitigation including defining low-risk and high-risk surgery for transmission and role of preoperative COVID-19 testing. This article is protected by copyright. All rights reserved."],"journal":"Head Neck","authors":["Topf, Michael C","Shenson, Jared A","Holsinger, F Christopher","Wald, Samuel H","Cianfichi, Lisa J","Rosenthal, Eben L","Sunwoo, John B"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298036","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hed.26184","keywords":["covid-19","sars-cov-2","clinical practice guidelines","head and neck cancer","surgical oncology"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664641388429443072,"score":471.7578},{"pmid":32303485,"pmcid":"PMC7151337","title":"French consensus on management of head and neck cancer surgery during COVID-19 pandemic.","text":["French consensus on management of head and neck cancer surgery during COVID-19 pandemic.","In the context of the current pandemic, there is a need for specific advice concerning treatment of patients with Head and Neck cancers. The rule is to limit as much as possible the number of patients in order to reduce the risks of contamination by the SARS-Cov-2 virus for both patients and the caregivers, who are particularly exposed in ENT. The aim is to minimize the risk of loss of opportunity for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched).","Eur Ann Otorhinolaryngol Head Neck Dis","Fakhry, N","Schultz, P","Moriniere, S","Breuskin, I","Bozec, A","Vergez, S","de Garbory, L","Hartl, D","Temam, S","Lescanne, E","Couloigner, V","Barry, B","32303485"],"abstract":["In the context of the current pandemic, there is a need for specific advice concerning treatment of patients with Head and Neck cancers. The rule is to limit as much as possible the number of patients in order to reduce the risks of contamination by the SARS-Cov-2 virus for both patients and the caregivers, who are particularly exposed in ENT. The aim is to minimize the risk of loss of opportunity for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched)."],"journal":"Eur Ann Otorhinolaryngol Head Neck Dis","authors":["Fakhry, N","Schultz, P","Moriniere, S","Breuskin, I","Bozec, A","Vergez, S","de Garbory, L","Hartl, D","Temam, S","Lescanne, E","Couloigner, V","Barry, B"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303485","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.anorl.2020.04.008","keywords":["covid","covid-19","ent","head and neck cancer","sars-cov-2"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"_version_":1664632934659784704,"score":431.30014},{"pmid":32329948,"title":"An Ethical Framework for Head and Neck Cancer Care Impacted by COVID-19.","text":["An Ethical Framework for Head and Neck Cancer Care Impacted by COVID-19.","The COVID-19 pandemic has upended head and neck cancer care delivery in ways unforeseen and unprecedented. The impact of these changes parallels other fields in oncology, but is disproportionate due to protective measures and limitations on potentially aerosolizing procedures and related interventions specific to the upper aerodigestive tract. The moral and professional dimensions of providing ethically appropriate and consistent care for our patients in the COVID-19 crisis are considered herein for head and neck oncology providers. This article is protected by copyright. All rights reserved.","Head Neck","Shuman, Andrew G","Campbell, Bruce H","32329948"],"abstract":["The COVID-19 pandemic has upended head and neck cancer care delivery in ways unforeseen and unprecedented. The impact of these changes parallels other fields in oncology, but is disproportionate due to protective measures and limitations on potentially aerosolizing procedures and related interventions specific to the upper aerodigestive tract. The moral and professional dimensions of providing ethically appropriate and consistent care for our patients in the COVID-19 crisis are considered herein for head and neck oncology providers. This article is protected by copyright. All rights reserved."],"journal":"Head Neck","authors":["Shuman, Andrew G","Campbell, Bruce H"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329948","week":"202017|Apr 20 - Apr 26","doi":"10.1002/hed.26193","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914977832960,"score":430.12915},{"pmid":32330858,"title":"Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","text":["Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care.","Oral Oncol","Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A","32330858"],"abstract":["The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care."],"journal":"Oral Oncol","authors":["Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330858","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.oraloncology.2020.104684","keywords":["covid-19 pandemic","head and neck cancer","head and neck oncology","mucosal squamous cell carcinoma","multilevel risk","risk stratification","sars-cov-2","surgical barriers","surgical risk","treatment paradigms"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914956861440,"score":416.2778}]}